140 related articles for article (PubMed ID: 32436563)
1. Twice-Daily vs. Once-Daily Dolutegravir in Patients With Human Immunodeficiency Virus-Tuberculosis Coinfection Receiving Rifampicin-Based Tuberculosis Therapy.
Shin SS; Modongo C; Zetola NM
Clin Infect Dis; 2020 Jun; 71(1):242-243. PubMed ID: 32436563
[No Abstract] [Full Text] [Related]
2. Real-world use and outcomes of dolutegravir-containing antiretroviral therapy in HIV and tuberculosis co-infection: a site survey and cohort study in sub-Saharan Africa.
Romo ML; Brazier E; Mahambou-Nsondé D; De Waal R; Sekaggya-Wiltshire C; Chimbetete C; Muyindike WR; Murenzi G; Kunzekwenyika C; Tiendrebeogo T; Muhairwe JA; Lelo P; Dzudie A; Twizere C; Rafael I; Ezechi OC; Diero L; Yotebieng M; Fenner L; Wools-Kaloustian KK; Shah NS; Nash D;
J Int AIDS Soc; 2022 Jul; 25(7):e25961. PubMed ID: 35848120
[TBL] [Abstract][Full Text] [Related]
3. Dosing of Dolutegravir in TB/HIV Coinfected Patients on Rifampicin: Twice Is (Always) Better Than Once.
Cattaneo D; Riva A; Columpsi P; Lapadula G; Filice C; Gervasoni C
J Acquir Immune Defic Syndr; 2020 Jul; 84(3):e17-e20. PubMed ID: 32205722
[No Abstract] [Full Text] [Related]
4. Dolutegravir-based Antiretroviral Therapy for Patients Coinfected With Tuberculosis and Human Immunodeficiency Virus: A Multicenter, Noncomparative, Open-label, Randomized Trial.
Dooley KE; Kaplan R; Mwelase N; Grinsztejn B; Ticona E; Lacerda M; Sued O; Belonosova E; Ait-Khaled M; Angelis K; Brown D; Singh R; Talarico CL; Tenorio AR; Keegan MR; Aboud M;
Clin Infect Dis; 2020 Feb; 70(4):549-556. PubMed ID: 30918967
[TBL] [Abstract][Full Text] [Related]
5. Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial.
Turkova A; Waalewijn H; Chan MK; Bollen PDJ; Bwakura-Dangarembizi MF; Kekitiinwa AR; Cotton MF; Lugemwa A; Variava E; Ahimbisibwe GM; Srirompotong U; Mumbiro V; Amuge P; Zuidewind P; Ali S; Kityo CM; Archary M; Ferrand RA; Violari A; Gibb DM; Burger DM; Ford D; Colbers A;
Lancet HIV; 2022 Sep; 9(9):e627-e637. PubMed ID: 35868341
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic features of dolutegravir with rifampicin and rifabutin among patients coinfected with human immunodeficiency virus and tuberculosis/mycobacterium avium complex.
Le X; Guo X; Sun J; Liu L; Shen Y; Wang J; Qi T; Wang Z; Tang Y; Song W; Yin L; Zhang L; Zhang R; Chen J
Int J Infect Dis; 2022 Mar; 116():147-150. PubMed ID: 34999246
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics, SAfety/tolerability, and EFficacy of high-dose RIFampicin in tuberculosis-HIV co-infected patients on efavirenz- or dolutegravir-based antiretroviral therapy: study protocol for an open-label, phase II clinical trial (SAEFRIF).
Nabisere R; Musaazi J; Denti P; Aber F; Lamorde M; Dooley KE; Aarnoutse R; Sloan DJ; Sekaggya-Wiltshire C
Trials; 2020 Feb; 21(1):181. PubMed ID: 32054536
[TBL] [Abstract][Full Text] [Related]
8. Clinical and Virological Outcomes of TB/HIV Coinfected Patients Treated With Dolutegravir-Based HIV Antiretroviral Regimens: Programmatic Experience From Botswana.
Modongo C; Wang Q; Dima M; Matsiri O; Kgwaadira B; Rankgoane-Pono G; Shin SS; Zetola NM
J Acquir Immune Defic Syndr; 2019 Oct; 82(2):111-115. PubMed ID: 31335593
[TBL] [Abstract][Full Text] [Related]
9. Managing Human Immunodeficiency Virus-associated Tuberculosis in the Dolutegravir Era.
Maartens G; Meintjes G
Clin Infect Dis; 2020 Feb; 70(4):557-558. PubMed ID: 30906946
[No Abstract] [Full Text] [Related]
10. Dolutegravir once daily with rifampicin for HIV and tuberculosis.
Naidoo A; Dooley KE
Lancet HIV; 2023 Jul; 10(7):e422-e423. PubMed ID: 37230100
[No Abstract] [Full Text] [Related]
11. Population Pharmacokinetic Model and Alternative Dosing Regimens for Dolutegravir Coadministered with Rifampicin.
Kawuma AN; Wasmann RE; Dooley KE; Boffito M; Maartens G; Denti P
Antimicrob Agents Chemother; 2022 Jun; 66(6):e0021522. PubMed ID: 35604212
[TBL] [Abstract][Full Text] [Related]
12. Dolutegravir for children with HIV-associated tuberculosis.
Meyers T; Krogstad P
Lancet HIV; 2022 Sep; 9(9):e599-e600. PubMed ID: 35868340
[No Abstract] [Full Text] [Related]
13. Immune reconstitution inflammatory syndrome: a report of TB-IRIS after switching from efavirenz to dolutegravir.
Zimba S; Mbewe N; Chishimba L; Chomba M; Saylor D
Trop Doct; 2021 Apr; 51(2):216-218. PubMed ID: 32903146
[TBL] [Abstract][Full Text] [Related]
14. Dolutegravir-induced hyperglycaemia in a patient living with HIV.
McLaughlin M; Walsh S; Galvin S
J Antimicrob Chemother; 2018 Jan; 73(1):258-260. PubMed ID: 29077869
[No Abstract] [Full Text] [Related]
15. The Effect of Pregnancy on the Pharmacokinetics of Total and Unbound Dolutegravir and Its Main Metabolite in Women Living With Human Immunodeficiency Virus.
Bollen P; Freriksen J; Konopnicki D; Weizsäcker K; Hidalgo Tenorio C; Moltó J; Taylor G; Alba-Alejandre I; van Crevel R; Colbers A; Burger D;
Clin Infect Dis; 2021 Jan; 72(1):121-127. PubMed ID: 32103260
[TBL] [Abstract][Full Text] [Related]
16. Compatibility of next-generation first-line antiretrovirals with rifampicin-based antituberculosis therapy in resource limited settings.
Maartens G; Boffito M; Flexner CW
Curr Opin HIV AIDS; 2017 Jul; 12(4):355-358. PubMed ID: 28403028
[TBL] [Abstract][Full Text] [Related]
17. ODYSSEY clinical trial design: a randomised global study to evaluate the efficacy and safety of dolutegravir-based antiretroviral therapy in HIV-positive children, with nested pharmacokinetic sub-studies to evaluate pragmatic WHO-weight-band based dolutegravir dosing.
Moore CL; Turkova A; Mujuru H; Kekitiinwa A; Lugemwa A; Kityo CM; Barlow-Mosha LN; Cressey TR; Violari A; Variava E; Cotton MF; Archary M; Compagnucci A; Puthanakit T; Behuhuma O; Saϊdi Y; Hakim J; Amuge P; Atwine L; Musiime V; Burger DM; Shakeshaft C; Giaquinto C; Rojo P; Gibb DM; Ford D;
BMC Infect Dis; 2021 Jan; 21(1):5. PubMed ID: 33446115
[TBL] [Abstract][Full Text] [Related]
18. Efavirenz 600 mg/day versus efavirenz 800 mg/day in HIV-infected patients with tuberculosis receiving rifampicin: 48 weeks results.
Manosuthi W; Kiertiburanakul S; Sungkanuparph S; Ruxrungtham K; Vibhagool A; Rattanasiri S; Thakkinstian A
AIDS; 2006 Jan; 20(1):131-2. PubMed ID: 16327334
[TBL] [Abstract][Full Text] [Related]
19. Long-Term Safety and Efficacy of Dolutegravir in Treatment-Experienced Adolescents With Human Immunodeficiency Virus Infection: Results of the IMPAACT P1093 Study.
Viani RM; Ruel T; Alvero C; Fenton T; Acosta EP; Hazra R; Townley E; Palumbo P; Buchanan AM; Vavro C; Singh R; Graham B; Anthony P; George K; Wiznia A;
J Pediatric Infect Dis Soc; 2020 Apr; 9(2):159-165. PubMed ID: 30951600
[TBL] [Abstract][Full Text] [Related]
20. Dolutegravir use in combination with rifampicin-based tuberculosis therapy: 3 years of real-world experience in a large UK teaching hospital.
Cevik M; McGann H
Sex Transm Infect; 2018 Sep; 94(6):420. PubMed ID: 30030303
[No Abstract] [Full Text] [Related]
[Next] [New Search]
